Table 4: **Gag**

	MAb ID	HXB2 Location	Author's Location	Sequence	Neutralizing	Immunogen	Species(Isotype)
122	32/5.8.42	Gag(dis)	p17(12-19 + 100–105 IIIB)	ELDRWEKI + ALDKIE	no	Viral lysate	murine(IgG)
	References: [Papsidero (1989)]						
	• 32/5.8.42: Inhibited infectivity of cell free virus – bound to both peptides, ELDRWEKI and ALDKIE –Papsidero89						
123	32/5.8.42	Gag(dis)	p17(12-19 + 100–105 IIIB)	ELDRWEKI + ALDKIE	no	Viral lysate	murine(IgG)
	References: [Papsidero (1989)]						
	• 32/5.8.42: Inhibited infectivity of cell free virus – bound ELDRWEKI and ALDKIE –Papsidero89						
124	CH9B2	Gag( )	p17( )			Inact CBL-1	murine(IgG_1)
	Donor: R. B. Ferns and R. S. Tedder						
	References: [Ferns (1987), Ferns (1989)]						
	• CH9B2: Reactive against p18 and p55 –Ferns87						
	• CH9B2: UK Medical Research Council AIDS reagent: ARP349						
125	G11G1	Gag( )	p17( )			?	rat( )
	References: [Shang (1991), Pincus (1996)]						
	• G11G1: Immunotoxins were generated by linking Env MAbs to ricin A – immunotoxins mediated cell killing, but only if the antigen was expressed at the cell surface – ricin-G11G1 did not mediate cell killing –Pincus96						
126	2A6	Gag( )	p17( )			?	( )
	Donor: A. O. Arthur, Frederick Cancer Research and Development Center, Frederick, MD						
	References: [Pincus (1998)]						
	• 2A6: Part of a panel of 17 MAbs used as controls testing for the dual specificity of MAb G11H3 for both p17 and mycoplasma –Pincus98						
127	G11H3	Gag(dis)	p17(Gag dis)			?	( )
	References: [Shang (1991), Pincus (1998)]						
	• G11H3: This MAb is cross-reactive between p17 and mycoplasma – this antibody binds strain specifically to the variable lipoprotein (Vlp) F of M. hyorhinis, in the region of the carboxy-terminal repeat CGGSTPTPEQGNNQG-GSTPTPEQGNSQVSK – the p17 epitope is discontinuous, but p17 and VlpF share the tetrapeptide SQVS –Pincus98						

	MAb ID	HXB2 Location	Author's Location	Sequence	Neutralizing	Immunogen	Species(Isotype)
128	HyHIV-19	Gag(dis)	p17(dis JMH1)		no	rec p17	murine(IgG_1)

References: [Liu (1995), Ota (1998)]

- HyHIV-19: Does not react with p17 peptides – Ka is3.7×10^6 M^{-1} for rec p17 – inhibited growth of HIV-1 JMH1 in MT-4 cells when added 24 hours after the initial culture –Ota98a

129	LH-104-A	Gag(dis)	p24(dis BRU)	DIRQGP + QGVGGP	no	104 amino acid peptide	murine($IgG_1\kappa$)

References: [Haaheim (1991)]

- LF-104-A: Hexapeptide scans revealed two reactive p24 peptides – cross-competition studies indicated the region 270–286 –Haaheim91
- LH-104-A: UK Medical Research Council AIDS reagent: ARP307

130	EH12E1	Gag(dis)	p24(Gag dis)			Inact CBL-1	murine(IgG_1)

Donor: R. B. Ferns and R. S. Tedder
References: [Ferns (1987), Ferns (1989)]

- EH12E1: Reacted with p55 and p24 in WB –Ferns87
- EH12E1: UK Medical Research Council AIDS reagent: ARP313

131	LH-104-C	Gag(dis)	p24(dis BRU)	GPKEPF + QGVGGP	no	104 amino acid peptide	murine($IgG_3\kappa$)

References: [Haaheim (1991)]

- LF-104-C: Hexapeptide scans revealed two reactive p24 peptides – cross-competition studies indicated the region 351–373 –Haaheim91
- LH-104-C: UK Medical Research Council AIDS reagent: ARP309

132	71-31	Gag( )	p24( )		no	HIV-1	human($IgG_1\lambda$)

References: [Gorny (1989), Robinson (1990b), Robinson (1991), Spear (1993), Gorny (1997), Gorny (1998), Bandres (1998)]

- 71-31: Did not enhance HIV-1 IIIB infection –Robinson90a
- 71-31: No enhancing or neutralizing activity –Robinson91
- 71-31: Did not mediate deposition of complement component C3 on HIV infected cells –Spear93
- 71-31: Included as a negative control in studies that demonstrate that CXCR4 can bind to gp120 in the absence of CD4-gp120 interactions, and that this binding can be enhanced by Env deglycosylation –Bandres98
- 71-31: NIH AIDS Research and Reference Reagent Program: 530

	MAb ID	HXB2 Location	Author's Location	Sequence	Neutralizing	Immunogen	Species(Isotype)
133	V7-8	Gag( )	p24( )		no	HIV-1 infection	murine($IgG_3\kappa$)
	References: [Robinson (1990b), Montefiori (1991)]						
	• V7-8: Did not enhance HIV-1 IIIB infection –Robinson90a						
	• V7-8: Reacted with HIV-1IIIB, RF, and MN –Montefiori91						
	• V7-8: NIH AIDS Research and Reference Reagent Program: 381						
134	98-4.9	Gag( )	p24( )		no	HIV-1 infection	murine($IgG_3\lambda$)
	References: [Gorny (1989)]						
135	98-4.3	Gag( )	p24( )		no	HIV-1 infection	human($IgG_1\lambda$)
	References: [Robinson (1991)]						
	• 98-4.3: No enhancing or neutralizing activity –Robinson91						
136	IE8G2	Gag( )	p24( )			Inact CBL-1	murine(IgG_1)
	Donor: R. B. Ferns and R. S. Tedder						
	References: [Ferns (1987), Ferns (1989)]						
	• IE8G2: Reacted with both p55 and p24 – broadly reactive – showed less than 75% homologous inhibition –Ferns87						
	• IE8G2: UK Medical Research Council AIDS reagent: ARP347						
137	human sera	Gag( )	p24( )			HIV-1 infection	human(IgG)
	References: [Binley (1997b)]						
	• Retention of anti-Env antibodies and loss of anti-Gag antibodies during progression was studied, and suggested to be the result of the loss of T-cell help and the unique ability of Env to stimulate B cells even in a backdrop of declining CD4 cells, because of the ability of Env to bind to the CD4 molecule –Binley97a						
138	241-D	Gag( )	p24( )		no		human($IgG_1\lambda$)
	Donor: Susan Zolla-Pazner (NYU Med. Center)						
	References: [Gorny (1989), Tyler (1990), Robinson (1991)]						
	• 241-D: An antibody by this name is available in the NIH AIDS Research and Reference Reagent Program, and they refer to the papers: Gorny89,Tyler90,Robinson91, but no p24 MAb by this name is discussed in these papers						
	• 241-D: MH AIDS Research and Reference Reagent program: 1244						

	MAb ID	HXB2 Location	Author's Location	Sequence	Neutralizing	Immunogen	Species(Isotype)
139	183-H12-5C	Gag( )	p24( )		no	unk	murine(IgG_1)
	Donor: Bruce Chesebro and Kathy Wehrly, Rocky Mountain Laboratories, Hamilton, Montana **References:** [Chesebro (1992), Toohey (1995), Wehrly & Chesebro(1997)] • 183-H12-5C: Cross-reacts with HIV1 and HIV-2 p24, and SIV p27 • 183-H12-5C: Used as antigen capture reagent for p24 ELISA –Chesebro92,Toohey95 • 183-H12-5C: Cross-reacts with HIV1 and HIV-2 p24, and SIV p27 –Wehrly97 • 183-H12-5C: NIH AIDS Research and Reference Reagent Program: 3537					
140	ED8	Gag(dis)	p7(Gag dis)		no	purified NCp7	murine(IgG)
	References: [Tanchou (1995)] • ED8: Binds NCp7 independent of Zn fingers, does not react with NCp15 –Tanchou95						
141	AC2	Gag(dis)	p7(Gag dis)		no	purified NCp7	murine(IgG)
	References: [Tanchou (1995)] • AC2: Binds NCp7 independent of Zn fingers, does not react with NCp15 –Tanchou95						
142	CD9	Gag(dis)	p7(Gag dis)		no	purified NCp7	murine(IgG)
	References: [Tanchou (1995)] • CD9: Binds NCp7 independent of Zn fingers, does not react with NCp15 –Tanchou95						
143	BE10	Gag(dis)	p7(Gag dis)		no	purified NCp7	murine(IgG)
	References: [Tanchou (1995)] • BE10: Binding NCp7 requires Zn fingers, does not react with NCp15, inhibits NCp7-tRNA interaction –Tanchou95						